Memo Therapeutics

About:

Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis.

Website: https://memo-therapeutics.com

Top Investors: Verve Ventures, Fresenius Medical Care, Zürcher Kantonal Bank, Schroders Capital, redalpine

Description:

Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

Total Funding Amount:

$109M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Schlieren, Zurich, Switzerland

Founded Date:

2012-01-01

Contact Email:

info(AT)memo-therapeutics.com

Founders:

Christoph Esslinger

Number of Employees:

11-50

Last Funding Date:

2024-05-07

IPO Status:

Private

Industries:

© 2025 bioDAO.ai